Aetna, CVS Health, CVS Pharmacy and associated parties have been served with an antitrust class action this week. The lawsuit accuses CVS Caremark of deliberately restricting independent pharmacies from accessing its network of Medicare Part D beneficiaries unless they agree to pay substantial fees, colloquially referred to as ‘DIR Fees’. This move, considered unprecedented, targets the heart of independent pharmacies by encroaching on their financial autonomy and freedom of operation.
Details of this emerging development were first revealed on law.com. This case presents another complex layer to the relationship between behemoth pharmacy chains and independent pharmacies, and is sure to be followed closely by legal professionals worldwide.
It is important for legal professionals working in corporations and large law firms to consider the implications of this case and how it will impact the broader healthcare industry, particularly how it relates to pharmacy networks and their broader stakeholders. This includes Medicare beneficiaries, independent pharmacies, and major healthcare entities themselves.